Devonian's Thykamine Shows Dose-Dependent Anti-Fibrotic Effects in Human Liver-on-a-Chip Study
Event summary
- Devonian's Thykamine™ demonstrated dose-dependent anti-fibrotic and anti-inflammatory effects in a human liver-on-a-chip model, reducing fibrosis biomarkers and collagen accumulation.
- The study, conducted by CN Bio Innovations, used the PhysioMimix® Liver-on-a-Chip platform to evaluate Thykamine™ at four concentrations over a 14-day period.
- Thykamine™ showed greater collagen reduction than Elafibranor, a clinically advanced compound, under identical experimental conditions.
- Devonian plans to advance additional preclinical studies to further characterize Thykamine™'s disease-modifying potential in MASH and other fibrotic diseases.
The big picture
Devonian's positive preclinical data for Thykamine™ comes as the global MASH treatment market is projected to grow at a 17.7% CAGR from 2025 to 2033, driven by rising rates of obesity and metabolic syndrome. The study's use of the PhysioMimix® Liver-on-a-Chip platform, recognized by the US FDA, underscores the growing importance of human organ-on-a-chip models in accelerating drug discovery and reducing reliance on animal testing. Devonian's strategic focus on fibroinflammatory autoimmune diseases positions it to capitalize on the unmet medical needs in this rapidly expanding market.
What we're watching
- Clinical Translation
- Whether Thykamine™'s efficacy in human liver-on-a-chip models will translate to clinical success in MASH patients.
- Competitive Positioning
- How Devonian's differentiated profile among emerging MASH therapeutics will impact its market positioning against established competitors like Elafibranor.
- Regulatory Pathway
- The pace at which Devonian can advance Thykamine™ through additional preclinical and clinical studies to support regulatory approval.
Related topics